9/23/2021 7:30:27 AM
RedHill Biopharma Announces Settlement Of Movantik Patent Litigation With Aurobindo
9/13/2021 7:10:04 AM
RedHill Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study Of Once-Daily Oral RHB-107 With South African Approval
9/7/2021 6:05:06 AM
RedHill Biopharma Presents Three New Analyses Of Analyses Of Movantik Phase 3 Study Data At PAINWeek 2021
8/26/2021 7:28:45 AM
RedHill Biopharma Q2 Loss/shr $0.06 Vs. Loss/shr $0.04 Last Year
8/26/2021 6:07:49 AM
RedHill Biopharma Says Opaganib Demonstrates Strong Inhibition Of COVID-19 Delta Variant
8/23/2021 7:12:37 AM
RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib For Ebola Virus And RHB-104 For Crohn's
8/23/2021 7:06:01 AM
RedHill Biopharma Unveils Two New U.S. Patents Covering Opaganib For Ebola Virus And RHB-104 For Crohn's
7/22/2021 9:20:42 AM
RedHill Biopharma Announces Settlement Of Movantik Patent Litigation With Apotex
7/19/2021 7:08:17 AM
RedHill Biopharma Announces Last Patient Out For Phase 2/3 COVID-19 Study Of Oral Opaganib
6/28/2021 7:09:39 AM
RedHill Biopharma Says Opaganib Inhibits COVID-19 Variants In Preclinical Study
6/21/2021 7:16:50 AM
RedHill Biopharma Presents Positive Oral Opaganib Phase 2 Data In COVID-19 At World Microbe Forum
6/7/2021 7:07:13 AM
RedHill Biopharma Completes Enrollment Of Oral Opaganib Phase 2/3 COVID-19 Study
5/27/2021 7:19:07 AM
RedHill Biopharma Q1 Loss Per Share $0.05, Flat With Last Year